Tulane Home Tulane Shield logo linking to site home page

Tulane Doctors - Radiation Oncology - Clinical Trials at Tulane

 

In-process at Tulane

  • S1827, MRI brain surveillance alone versus MRI surveillance and prophylactic cranial irradiation (PCI): A randomized phase III trial in small-cell lung cancer (MAVERICK). Anticipate opening this trial, post-COVID hold. Submitted to IRB.
     
  • Testing the addition of the drugs apalutamide and abiraterone-acetate with prednisone, to the usual hormone therapy and radiation therapy after surgery for prostate cancer. Currently working to complete IRB submission. Anticipate submission post-COVID hold.”
     

Examples of Clinical Trials

  • VISION: An international, prospective, open-label, multi-center, randomized phase III Study of 177Lu-PSMA-167 in the treatment of patients with progressive PSMA-positive metastatic castrate resistant prostate cancer (mCRPC).
     
  • Phase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer.
     
  • A Phase 1, open-label, first-in-human, multi-center, study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of a thorium-227 labeled antibody-chelator conjugate, BAY 2315497, injection, in patients with metastatic castration resistant prostate cancer.
     
  • DTI-025: A PHASE I TRIAL TO EVALUATE SAFETY AND TOLERANCE OF INTRAVENOUS 4-DEMETHYL-4-CHOLESTERYLOXYCARBONYLPENCLOMEDINE (DM-CHOC-PEN) Plus RADIATION THERAPY (SRS or WBRT) IN ADULT SUBJECTS WITH MALIGNANCIES INVOLVING THE CNS.
     
  • METIS: Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC).
     
  • LUNAR: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies, for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure.
     
  • IDR-OM-02 A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck.